Literature DB >> 33426502

Cannabis and Vulvodynia Symptoms: A Preliminary Report.

Eliza Barach1, Melissa N Slavin2, Mitch Earleywine1.   

Abstract

Medical marijuana has a long history of use as an analgesic for chronic pain disorders, including dyspareunia (pain during intercourse), a hallmark of the rare chronic pain disorder vulvodynia. Many women's health topics remain under investigated. Few studies address cannabis's potential to treat vulvodynia symptoms despite their dramatic impact on quality of life. Women who had used cannabis and who reported experiencing vulvodynia symptoms (N = 38) completed an online survey assessing symptoms, expectancies regarding cannabis-associated relief from vulvodynia symptoms, cannabis use, and cannabis-related problems. Generally, women expected cannabis to have moderate to large effects on vulvodynia symptoms (d = .63-1.19). Nevertheless, women expected greater relief for burning/stabbing pain than for itching and pain associated with tampon insertion, as well greater relief for dyspareunia than for pain associated with tampon insertion. Those whose symptoms were worse expected more relief from cannabis treatment. Expectations of cannabis-induced relief did not increase frequency of use or problems. These data support the idea that further work is warranted, including placebo-controlled randomized clinical trials to rule out any placebo effects and identify potential adverse side effects from a cannabis treatment for vulvodynia.

Entities:  

Keywords:  alternative treatment; cannabis; expectancies; vulvar pain; vulvodynia

Year:  2020        PMID: 33426502      PMCID: PMC7787394          DOI: 10.26828/cannabis.2020.02.001

Source DB:  PubMed          Journal:  Cannabis        ISSN: 2578-0026


  35 in total

1.  Neurochemical characterization of the vestibular nerves in women with vulvar vestibulitis syndrome.

Authors:  N Bohm-Starke; M Hilliges; C Falconer; E Rylander
Journal:  Gynecol Obstet Invest       Date:  1999       Impact factor: 2.031

2.  Influence of oral contraceptive use on the risk of adult-onset vulvodynia.

Authors:  Bernard L Harlow; Allison F Vitonis; Elizabeth Gunther Stewart
Journal:  J Reprod Med       Date:  2008-02       Impact factor: 0.142

Review 3.  2013 Vulvodynia Guideline update.

Authors:  Colleen K Stockdale; Herschel W Lawson
Journal:  J Low Genit Tract Dis       Date:  2014-04       Impact factor: 1.925

Review 4.  A systematic review of the utility of antidepressant pharmacotherapy in the treatment of vulvodynia pain.

Authors:  Raphael J Leo; Seema Dewani
Journal:  J Sex Med       Date:  2012-09-13       Impact factor: 3.802

5.  Deceptive vulvar papillomavirus infection. A possible explanation for certain cases of vulvodynia.

Authors:  G R di Paola; N G Rueda
Journal:  J Reprod Med       Date:  1986-10       Impact factor: 0.142

Review 6.  Vulvodynia: new concepts and review of the literature.

Authors:  Vlada Groysman
Journal:  Dermatol Clin       Date:  2010-10       Impact factor: 3.478

7.  Prevalence of symptoms consistent with a diagnosis of vulvodynia: population-based estimates from 2 geographic regions.

Authors:  Bernard L Harlow; Christine G Kunitz; Ruby H N Nguyen; Sarah A Rydell; Rachel M Turner; Richard F MacLehose
Journal:  Am J Obstet Gynecol       Date:  2013-09-28       Impact factor: 8.661

8.  2015 ISSVD, ISSWSH, and IPPS Consensus Terminology and Classification of Persistent Vulvar Pain and Vulvodynia.

Authors:  Jacob Bornstein; Andrew T Goldstein; Colleen K Stockdale; Sophie Bergeron; Caroline Pukall; Denniz Zolnoun; Deborah Coady
Journal:  J Sex Med       Date:  2016-03-25       Impact factor: 3.802

9.  Effects of vulvodynia on quality of life.

Authors:  Maya Ponte; Erika Klemperer; Anju Sahay; Mary-Margaret Chren
Journal:  J Am Acad Dermatol       Date:  2008-11-20       Impact factor: 11.527

Review 10.  A review of the available clinical therapies for vulvodynia management and new data implicating proinflammatory mediators in pain elicitation.

Authors:  M L Falsetta; D C Foster; A D Bonham; R P Phipps
Journal:  BJOG       Date:  2016-06-17       Impact factor: 6.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.